Malignancy Prevalence in the Dialyzed Population and in Waitlisted Potential Kidney Transplant Recipients
•Waitlisted patients represent a very select and healthier dialyzed population.•Malignancy has become a more common comorbidity in dialyzed patients, which may have important clinical implication regarding therapy.•Guidelines for cancer screening in potential transplant recipients should be develope...
Gespeichert in:
Veröffentlicht in: | Transplantation proceedings 2022-05, Vol.54 (4), p.930-933 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Waitlisted patients represent a very select and healthier dialyzed population.•Malignancy has become a more common comorbidity in dialyzed patients, which may have important clinical implication regarding therapy.•Guidelines for cancer screening in potential transplant recipients should be developed, as nowadays there are scarcity of data in this matter.
Malignancy is the second cause of death in the dialyzed population. However, data on the prevalence of cancer are very scarce. Kidney transplantation improves quality of life, prolongs survival, and is cost-effective but bears some serious complications including malignancy. Therefore, active screening for cancer is of utmost importance. The aim of this study was to assess the prevalence of malignancy in dialyzed patients in relation to status on the on the waiting list and type of dialysis. This cross-sectional study was conducted in 108 hemodialyzed patients (mean age 65 years, 47 women) and 47 peritoneally dialyzed patients (mean age 51 years, 25 women). Among the population studied, 20 patients were actively waitlisted, including 14 peritoneal dialysis patients. Patients who had been active on the cadaver kidney waiting list and not listed did not differ in regard to sex, dialysis vintage, and causes of end-stage renal failure, but were significantly younger. Among hemodialysis patients, 24 of them had a history of malignancy and 10 in the peritoneal dialysis population. The most common were renal cell carcinoma in 6, breast cancer in 4, lung cancer in 3, prostate cancer in 3, hepatocellular cancer in 2, colorectal cancer in 2, esophageal cancer in 2, and others 14. In waitlisted patients, only 2 hemodialysis patients had a history of malignancy. Waitlisted patients represent a very selected and healthier dialyzed population. Malignancy has become a more common comorbidity in dialyzed patients, which may have important clinical implication regarding therapy. Guidelines for cancer screening in potential transplant recipients should be developed, as nowadays there are scarcity of data in this matter. |
---|---|
ISSN: | 0041-1345 1873-2623 |
DOI: | 10.1016/j.transproceed.2022.01.025 |